{'fraction_non_alphanumeric': 0.022354694485842028, 'fraction_numerical': 0.0014903129657228018, 'mean_word_length': 5.524271844660194, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hormonal treatment of premenstrual syndrome

drome (PMS) remains to be determined. It is generally accepted, however, that changes in blood levels of the hormones of the pituitary-gonadal axis that characterize the ovulatory menstrual cycle play a pivotal role. Accordingly, various attempts have been undertaken to change the hormonal milieu in PMS patients in order to suppress or lessen their symptoms. Hormonal treatments for PMS can be divided broadly into three categories: supplementation of the endocrine milieu; suppression of ovulation with maintenance of high gonadal steroid levels; suppression of ovulation with maintenance of low gonadal steroid levels (1).